Abstract
Since the recognition of HIV-1 integrase as a novel and rational target for HIV therapeutics, remarkable progress has been made in the development of integrase inhibitors. Computational techniques have played a critical role in accelerating research in this area. However, most previous computational studies were based solely on ligand information. In the present work, we describe the application of one of our recently developed receptor-based 3D-quantitative structure activity relationships (QSAR) methods, i.e. comparative residue interaction analysis (CoRIA), in exploring the events involved in ligand-integrase binding. In this methodology, the non-bonded interaction energies (van der Waals and Coulombic) of the inhibitors with individual active site residues of the integrase enzyme are calculated and, along with other thermodynamic descriptors, are correlated with biological activity using chemometric methods. Different combinations of descriptors were used to develop three types of QSAR models, all of which were found to be statistically significant by internal and external validation. This is the first report of such a dedicated receptor-based 3D-QSAR approach being applied to comprehend the integrase–inhibitor recognition process. In addition, the study was performed on 13-different series of inhibitors, thereby exploring the most structurally diverse data set ever used in understanding the inhibition of HIV-1 integrase. The major advantage of this technique is that it can quantitatively extract crucial residues and identify the nature of interactions between the ligand and receptor that modulate activity. The models suggest that Asp64, Thr66, Val77, Asp116, Glu152 and Lys159 are the key residues influencing the binding of ligands with the integrase enzyme, and the majority of these results are in line with earlier studies. The approach facilitates easy lead-to-hit conversion and design of novel inhibitors by optimisation of the interaction of ligands with these specific residues of the integrase enzyme.
Similar content being viewed by others
References
Gottlieb MS, Schroff R, Schanker HM et al (1981) Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305:1425–1430
Masur H, Michelis MA, Greene JB et al (1981) An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 305:1431–1438
Siegal FP, Lopez C, Hammer GS et al (1981) Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 305:1439–1444
UNAIDS/WHO, AIDS Epidemic Update, 2007, WHO, Geneva
Richman DD (2001) HIV chemotherapy. Nature 410:995–1001. doi:10.1038/35073673
Carr A (2003) Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2:624–634. doi:10.1038/nrd1151
Jain RG, Furfine ES, Pedneault L et al (2001) Metabolic complications associated with antiretroviral therapy. Antiviral Res 51:151–177. doi:10.1016/S0166-3542(01)00148-6
Mansky LM (2002) HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resist Updat 5:219–223. doi:10.1016/S1368-7646(02)00118-8
Pommier Y, Johnson AA, Marchand C (2005) Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 4:236–248. doi:10.1038/nrd1660
Thomas M, Brady L (1997) HIV integrase: a target for AIDS therapeutics. Trends Biotechnol 15:167–172. doi:10.1016/S0167-7799(97)01016-0
d’Angelo J, Mouscadet JF, Desmaele D et al (2001) HIV-1 integrase: the next target for AIDS therapy? Pathol Biol 49:237–246. doi:10.1016/S0369-8114(01)00135-3
Pluymers W, Clercq ED, Debyser Z (2001) HIV-1 integration as a target for antiretroviral therapy: a review. Curr Drug Targets Infect Disord 1:133–149. doi:10.2174/1568005014606044
Pommier Y, Marchand C, Neamati N (2000) Retroviral integrase inhibitors year 2000: update and perspectives. Antiviral Res 47:139–148. doi:10.1016/S0166-3542(00)00112-1
Anker M, Corales RB (2008) Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs 17:97–103. doi:10.1517/13543784.17.1.97
Rowley M (2008) The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem 46:1–28. doi:10.1016/S0079-6468(07)00001-X
Nicklaus MC, Neamati N, Hong H et al (1997) HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem 40:920–929. doi:10.1021/jm960596u
Hong H, Neamati N, Wang S et al (1997) Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem 40:930–936. doi:10.1021/jm960754h
Neamati N, Hong H, Mazumder A et al (1997) Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J Med Chem 40:942–951. doi:10.1021/jm960759e
Neamati N, Hong H, Sunder S et al (1997) Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol Pharmacol 52:1041–1055
Barreca ML, Rao A, De Luca L et al (2004) Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Comput Sci 44:1450–1455. doi:10.1021/ci034296e
Barreca ML, Ferro S, Rao A et al (2005) Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J Med Chem 48:7084–7088. doi:10.1021/jm050549e
Mustata GI, Brigo A, Briggs JM (2004) HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg Med Chem Lett 14:1447–1454. doi:10.1016/j.bmcl.2004.01.027
Dayam R, Sanchez T, Clement O et al (2005) Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J Med Chem 48:111–120. doi:10.1021/jm0496077
Dayam R, Sanchez T, Neamati N (2005) Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. J Med Chem 48:8009–8015. doi:10.1021/jm050837a
Carlson HA, Masukawa KM, Rubins K et al (2000) Developing a dynamic pharmacophore model for HIV-1 integrase. J Med Chem 43:2100–2114. doi:10.1021/jm990322h
Deng J, Lee KW, Sanchez T et al (2005) Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J Med Chem 48:1496–1505. doi:10.1021/jm049410e
Deng J, Sanchez T, Neamati N et al (2006) Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. J Med Chem 49:1684–1692. doi:10.1021/jm0510629
Buolamwini JK, Raghavan K, Fesen MR et al (1996) Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. Pharm Res 13:1892–1895. doi:10.1023/A:1016005813432
Marrero-Ponce Y (2004) Linear indices of the “molecular pseudograph’s atom adjacency matrix”: definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J Chem Inf Comput Sci 44:2010–2026. doi:10.1021/ci049950k
Cyrillo M, Galvão DS (1999) Structure–activity relationship study of some inhibitors of HIV-1 integrase. J Mol Struc-Theochem 464:267–272. doi:10.1016/S0166-1280(98)00558-2
Yuan H, Parrill AL (2000) QSAR development to describe HIV-1 integrase inhibition. J Mol Struct Theochem 592:273–282. doi:10.1016/S0166-1280(00)00553-4
Makhija MT, Kulkarni VM (2002) QSAR of HIV-1 integrase inhibitors by genetic function approximation method. Bioorg Med Chem 10:1483–1497. doi:10.1016/S0968-0896(01)00415-1
Yuan H, Parrill AL (2002) QSAR studies of HIV-1 integrase inhibition. Bioorg Med Chem 10:4169–4183. doi:10.1016/S0968-0896(02)00332-2
Filimonov DA, Akimov DV, Poroikov VV (2004) The method of self-consistent regression for the quantitative analysis of relationships between structure and properties of chemicals. Pharm Chem J 38:21–24. doi:10.1023/B:PHAC.0000027639.17115.5d
Verma RP, Hansch C (2004) An approach towards the quantitative structure-activity relationships of caffeic acid and its derivatives. ChemBioChem 5:1188–1195. doi:10.1002/cbic.200400094
Raghavan K, Buolamwini JK, Fesen MR et al (1995) Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. J Med Chem 38:890–897. doi:10.1021/jm00006a006
Ma XH, Zhang XY, Tan JJ et al (2004) Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. Acta Pharmacol Sin 25:950–958
Makhija MT, Kulkarni VM (2002) 3D-QSAR and molecular modelling of HIV-1 integrase inhibitors. J Comput Aided Mol Des 16:181–200. doi:10.1023/A:1020137802155
Makhija MT, Kulkarni VM (2001) Molecular electrostatic potentials as input for the alignment of HIV-1 integrase inhibitors in 3D QSAR. J Comput Aided Mol Des 15:961–978. doi:10.1023/A:1014888730876
Makhija MT, Kulkarni VM (2001) Eigen value analysis of HIV-1 integrase inhibitors. J Chem Inf Comput Sci 41:1569–1577. doi:10.1021/ci0001334
Kuo CL, Assefa H, Kamath S et al (2004) Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. J Med Chem 47:385–399. doi:10.1021/jm030378i
Buolamwini JK, Assefa H (2002) CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem 45:841–852. doi:10.1021/jm010399h
Daeyaert FFD, Vinkers M, De Jonge MR et al (2004) Ligand-based computation of HIV-1 integrase inhibition strength within a series of β-ketoamide derivatives. Internet Electron J Mol Des 3:528–543
Yuan H, Parrill A (2005) Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors. J Mol Graph Model 23:317–328. doi:10.1016/j.jmgm.2004.10.003
Di Santo R, Costi R, Artico M et al (2005) Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. Farmaco 60:409–417. doi:10.1016/j.farmac.2005.03.008
Iyer M, Hopfinger AJ (2007) Treating chemical diversity in QSAR analysis: modelling diverse HIV-1 integrase inhibitors using 4D fingerprints. J Chem Inf Model 47:1945–1960. doi:10.1021/ci700153g
Leonard JT, Roy K (2008) Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur J Med Chem 43:81–92. doi:10.1016/j.ejmech.2007.02.021
Niedbala H, Polanski J, Gieleciak R et al (2006) Comparative molecular surface analysis (CoMSA) for virtual combinatorial library screening of styrylquinoline HIV-1 blocking agents. Comb Chem High Throughput Screen 9:753–770. doi:10.2174/138620706779026042
Saiz-Urra L, Gonzalez MP, Fall Y et al (2007) Quantitative structure-activity relationship studies of HIV-1 integrase inhibition. 1. GETAWAY descriptors. Eur J Med Chem 42:64–70. doi:10.1016/j.ejmech.2006.08.005
Nunthaboot N, Tonmunphean S, Parasuk V et al (2006) Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA. Eur J Med Chem 41:1359–1372. doi:10.1016/j.ejmech.2006.06.014
Sotriffer CA, Ni H, McCammon JA (2000) HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J Am Chem Soc 122:6136–6137. doi:10.1021/ja001152x
Vajragupta O, Boonchoong P, Morris GM et al (2005) Active site binding modes of curcumin in HIV-1 protease and integrase. Bioorg Med Chem Lett 15:3364–3368. doi:10.1016/j.bmcl.2005.05.032
Keseru GM, Kolossvary I (2001) Fully flexible low-mode docking: application to induced fit in HIV integrase. J Am Chem Soc 123:12708–12709. doi:10.1021/ja0160086
Sotriffer CA, Ni H, McCammon JA (2000) Active site binding modes of HIV-1 integrase inhibitors. J Med Chem 43:4109–4117. doi:10.1021/jm000194t
Guenther S, Nair V (2002) Binding modes of two novel dinucleotide inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 12:2233–2236. doi:10.1016/S0960-894X(02)00353-0
Dayam R, Neamati N (2004) Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design. Bioorg Med Chem 12:6371–6381. doi:10.1016/j.bmc.2004.09.035
Schames JR, Henchman RH, Siegel JS et al (2004) Discovery of a novel binding trench in HIV integrase. J Med Chem 47:1879–1881. doi:10.1021/jm0341913
da Silva CH, Del Ponte G, Neto AF et al (2005) Rational design of novel diketoacid-containing ferrocene inhibitors of HIV-1 integrase. Bioorg Chem 33:274–284. doi:10.1016/j.bioorg.2005.03.001
Deng J, Kelley JA, Barchi JJ et al (2006) Mining the NCI antiviral compounds for HIV-1 integrase inhibitors. Bioorg Med Chem 14:3785–3792. doi:10.1016/j.bmc.2006.01.040
Long YQ, Jiang XH, Dayam R et al (2004) Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. J Med Chem 47:2561–2573. doi:10.1021/jm030559k
Sechi M, Derudas M, Dallocchio R et al (2004) Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors. J Med Chem 47:5298–5310. doi:10.1021/jm049944f
Verschueren WG, Dierynck I, Amssoms KI et al (2005) Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase. J Med Chem 48:1930–1940. doi:10.1021/jm049559q
Makhija MT, Kasliwal RT, Kulkarni VM et al (2004) De novo design and synthesis of HIV-1 integrase inhibitors. Bioorg Med Chem 12:2317–2333. doi:10.1016/j.bmc.2004.02.005
Lins RD, Briggs JM, Straatsma TP et al (1999) Molecular dynamics studies on the HIV-1 integrase catalytic domain. Biophys J 76:2999–3011
Lins RD, Straatsma TP, Briggs JM (2000) Similarities in the HIV-1 and ASV integrase active sites upon metal cofactor binding. Biopolymers 53:308–315. doi:10.1002/(SICI)1097-0282(20000405)53:4<308::AID-BIP3>3.0.CO;2-H
Lins RD, Adesokan A, Soares TA et al (2000) Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. Pharmacol Ther 85:123–131. doi:10.1016/S0163-7258(99)00059-5
Ni H, Sotriffer CA, McCammon JA (2001) Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: a molecular dynamics study. J Med Chem 44:3043–3047. doi:10.1021/jm010205y
Barreca ML, Lee KW, Chimirri A et al (2003) Molecular dynamics studies of the wild-type and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: mechanism for inhibition and drug resistance. Biophys J 84:1450–1463
Brigo A, Lee KW, Iurcu Mustata G et al (2005) Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/M154I catalytic domain. Biophys J 88:3072–3082. doi:10.1529/biophysj.104.050286
Brigo A, Lee KW, Fogolari F et al (2005) Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: binding modes and drug resistance to a diketo acid inhibitor. Proteins 59:723–741. doi:10.1002/prot.20447
Lee MC, Deng J, Briggs JM et al (2005) Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants. Biophys J 88:3133–3146. doi:10.1529/biophysj.104.058446
Wijitkosoom A, Tonmunphean S, Truong TN et al (2006) Structural and dynamical properties of a full-length HIV-1 integrase: molecular dynamics simulations. J Biomol Struct Dyn 23:613–624
Nunthaboot N, Pianwanit S, Parasuk V et al (2007) Computational studies of HIV-1 integrase and its nhibitors. Curr Computer-Aided Drug Des 3:160–190. doi:10.2174/157340907781695459
Almerico AM, Tutone M, Ippolito M et al (2007) Molecular modelling and QSAR in the discovery of HIV-1 integrase inhibitors. Curr Computer-Aided Drug Des 3:214–233. doi:10.2174/157340907781695468
Datar PA, Khedkar SA, Malde AK et al (2006) Comparative residue interaction analysis (CoRIA): a 3D-QSAR approach to explore the binding contributions of active site residues with ligands. J Comput Aided Mol Des 20:343–360. doi:10.1007/s10822-006-9051-5
Khedkar SA, Malde AK, Coutinho EC (2007) Design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3D-QSAR, and de Novo Design. J Chem Inf Model 47:1839–1846. doi:10.1021/ci600568u
Verma J, Khedkar VM, Prabhu AS et al (2008) A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA and its variants. J Comput Aided Mol Des 22:91–104. doi:10.1007/s10822-008-9172-0
Ortiz AR, Pisabarro TM, Gago F et al (1995) Prediction of drug binding affinities by comparative binding energy analysis. J Med Chem 38:2681–2691. doi:10.1021/jm00014a020
Gohlke H, Klebe G (2002) DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J Med Chem 45:4153–4170. doi:10.1021/jm020808p
Zhao H, Neamati N, Mazumder A et al (1997) Arylamide inhibitors of HIV-1 integrase. J Med Chem 40:1186–1194. doi:10.1021/jm960449w
Meadows DC, Mathews TB, North TW et al (2005) Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors. J Med Chem 48:4526–4534. doi:10.1021/jm049171v
Zhao H, Neamati N, Hong H et al (1997) Coumarin-based inhibitors of HIV integrase. J Med Chem 40:242–249. doi:10.1021/jm960450v
Neamati N, Hong H, Owen JM et al (1998) Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J Med Chem 41:3202–3209. doi:10.1021/jm9801760
Zhao H, Neamati N, Sunder S et al (1997) Hydrazide-containing inhibitors of HIV-1 integrase. J Med Chem 40:937–941. doi:10.1021/jm960755+
Neamati N, Turpin JA, Winslow HE et al (1999) Thiazolothiazepine inhibitors of HIV-1 integrase. J Med Chem 42:3334–3341. doi:10.1021/jm990047z
Dayam R, Sanchez T, Neamati N (2006) Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors. ChemMedChem 1:238–244. doi:10.1002/cmdc.200500018
Mazumder A, Raghavan K, Weinstein J et al (1995) Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 49:1165–1170. doi:10.1016/0006-2952(95)98514-A
Mazumder A, Gazit A, Levitzki A et al (1995) Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 34:15111–15122. doi:10.1021/bi00046a018
Neamati N, Mazumder A, Zhao H et al (1997) Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother 41:385–393
Cerius2 version 4.6, Accelrys, San Diego, CA
Sybyl version 7.1, Tripos, St. Louis, MO
Halgren TA (1996) Merck Molecular Force Field. V. Extension of MMFF94 using experimental data, additional computational data and empirical rules. J Comput Chem 17:616–641. doi:10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X
Goldgur Y, Craigie R, Cohen GH et al (1999) Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 96:13040–13043. doi:10.1073/pnas.96.23.13040
Berman HM, Westbrook J, Feng Z et al (2000) The protein data bank. Nucleic Acids Res 28:235–242. doi:10.1093/nar/28.1.235
Sybyl version 6.9, Tripos, St. Louis, MO
GOLD version 3.1, Cambridge Crystallographic Data Centre (CCDC), UK
Maple JR, Hwang M-J, Stockfisch TP et al (1994) Derivation of class II force fields. I. Methology and quantum force field for the alkyl functional group and alkane molecules. J Comput Chem 15:162–182. doi:10.1002/jcc.540150207
InsightII version 2005L, Accelrys, San Diego, CA
Still WC, Tempczyk A, Hawley RC et al (1990) Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 112:6127–6129. doi:10.1021/ja00172a038
Quasar version 5.0, Biographics Laboratory 3R, Basel, Switzerland
Searle MS, Williams DH (1992) The cost of conformational order: entropy changes in molecular associations. J Am Chem Soc 114:10690–10697. doi:10.1021/ja00053a002
Rogers D, Hopfinger AJ (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci 34:854–866. doi:10.1021/ci00020a020
Wold S, Johansson E, Cocchi M (1993) PLS: Partial least squares projections to latent structures. In: Kubinyi H (ed) 3D QSAR in drug design: Theory, methods and applications. ESCOM Science, Leiden, pp 523–550
Richard D, Cramer RD III, Bunce JD et al (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 7:18–25. doi:10.1002/qsar.19880070105
Lee DJ, Robinson WE Jr (2006) Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother 50:134–142. doi:10.1128/AAC.50.1.134-142.2006
Drake RR, Neamati N, Hong H et al (1998) Identification of a nucleotide binding site in HIV-1 integrase. Proc Natl Acad Sci USA 95:4170–4175. doi:10.1073/pnas.95.8.4170
Savarino A (2007) In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 4:21–35. doi:10.1186/1742-4690-4-21
Sayasith K, Sauve G, Yelle J (2000) Characterization of mutant HIV-1 integrase carrying amino acid changes in the catalytic domain. Mol Cells 10:525–532
Acknowledgements
D.K.D thanks the All India Council of Technical Education (AICTE, New Delhi), J.V. thanks the Council of Scientific and Industrial Research (CSIR, New Delhi), and A.S. thanks the Indian National Science Academy (INSA, New Delhi) for financial support. The computational facilities were made possible through grants from the Department of Science and Technology (SR/FST/LSI-163/2003) and the Council of Scientific and Industrial Research (01(1986)/05/EMR-II).
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 654 KB)
Rights and permissions
About this article
Cite this article
Dhaked, D.K., Verma, J., Saran, A. et al. Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA). J Mol Model 15, 233–245 (2009). https://doi.org/10.1007/s00894-008-0399-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-008-0399-4